Anil Shanker to Immunotherapy
This is a "connection" page, showing publications Anil Shanker has written about Immunotherapy.
Connection Strength
4.808
-
Renrick AN, Dunbar ZT, Shanker A. Update?on the current revolution in cancer immunotherapy. Immunotherapy. 2019 01; 11(1):15-20.
Score: 0.611
-
Shanker A, Thounaojam MC, Mishra MK, Dikov MM. Innate-Adaptive Immune Crosstalk 2016. J Immunol Res. 2017; 2017:3503207.
Score: 0.542
-
Pulliam SR, Uzhachenko RV, Adunyah SE, Shanker A. Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2016 Jan; 169:61-72.
Score: 0.492
-
Shanker A, Thounaojam MC, Mishra MK, Dikov MM, Uzhachenko RV. Innate-Adaptive Immune Crosstalk. J Immunol Res. 2015; 2015:982465.
Score: 0.491
-
Shanker A, Dikov MM, Carbone DP. Promise of Immunotherapy in Lung Cancer. Prog Tumor Res. 2015; 42:95-109.
Score: 0.485
-
Pellom ST, Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015; 7(9):1011-22.
Score: 0.485
-
de Aquino MT, Malhotra A, Mishra MK, Shanker A. Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett. 2015 Aug; 166(2):117-33.
Score: 0.478
-
Shanker A, Marincola FM. Cooperativity of adaptive and innate immunity: implications for cancer therapy. Cancer Immunol Immunother. 2011 Aug; 60(8):1061-74.
Score: 0.362
-
Shanker A, Sayers T. Sensitizing tumor cells to immune-mediated cytotoxicity. Adv Exp Med Biol. 2007; 601:163-71.
Score: 0.266
-
Shanker A, Singh SM. Immunopotentiation in mice bearing a spontaneous transplantable T-cell lymphoma: role of thymic extract. Neoplasma. 2003; 50(4):272-9.
Score: 0.202
-
Tewary P, Brooks AD, Xu YM, Wijeratne EMK, Babyak AL, Back TC, Chari R, Evans CN, Henrich CJ, Meyer TJ, Edmondson EF, de Aquino MTP, Kanagasabai T, Shanker A, Gunatilaka AAL, Sayers TJ. Small-Molecule Natural Product Physachenolide C Potentiates Immunotherapy Efficacy by Targeting BET Proteins. Cancer Res. 2021 06 15; 81(12):3374-3386.
Score: 0.179
-
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung?Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). Clin Lung Cancer. 2020 11; 21(6):520-526.
Score: 0.169
-
Biktasova AK, Dudimah DF, Uzhachenko RV, Park K, Akhter A, Arasada RR, Evans JV, Novitskiy SV, Tchekneva EE, Carbone DP, Shanker A, Dikov MM. Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. Cancer Res. 2015 Nov 15; 75(22):4728-41.
Score: 0.030
-
Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008 Jan 01; 180(1):163-70.
Score: 0.018